Skip to main content

Table 1 Clinical characteristics of the study population

From: Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis

  Tofacitinib (n = 161) Baricitinib (n = 81) P value
Female, n (%) 133 (82.6) 68 (84.0) 0.857
Age (years) 67 [58–73] 66 [56–74] 0.667
Duration of RA (years) 12 [6–18] 11 [4–18] 0.243
Concomitant MTX use, n (%) 109 (67.7) 37 (45.7) 0.001
Mean MTX dose (mg/week) 8.62 ± 2.49 8.05 ± 2.69 0.427
Concomitant oral steroid use, n (%) 86 (53.4) 38 (46.9) 0.345
Mean oral steroid dose (mg/day) 4.80 ± 2.72 4.80 ± 3.08 0.844
ACPA positive, n (%) 124 (77.0) 65 (80.2) 0.624
RF positive, n (%) 122 (75.8) 70 (86.4) 0.064
No prior use of b/tsDMARDs, n (%) 37 (23.0) 18 (22.2) > 0.999
Number of previous use of b/tsDMARDs 2.00 [1.00–3.00] 2.00 [1.00–3.00] 0.968
DAS28-ESR 5.17 [4.08–6.11] 5.13 [4.21–5.98] 0.622
SDAI 20 [14–32] 19 [14–29] 0.507
CDAI 19 [12–30] 18 [12–27] 0.497
mHAQ 0.60 [0.1–1.3] 0.62 [0.12–1.38] 0.372
  1. Data are median [interquartile range] unless otherwise indicated
  2. RA rheumatoid arthritis, MTX methotrexate, ACPA anti-citrullinated protein antibodies, RF rheumatoid factor, b/tsDMARDs biological and/or targeted synthetic disease-modifying antirheumatic drugs, DAS disease activity score, ESR erythrocyte sedimentation rate, SDAI Simplified Disease Activity Index, CDAI Clinical Disease Activity Index, mHAQ modified Health Assessment Questionnaire